Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BMS-986446 · PRX-005

Other · developed by BRISTOL MYERS SQUIBB

Phase 2 Most advanced trial
BMY Developer

What is BMS-986446?

BMS-986446 (also known as PRX-005) is an agent studied in early onset Alzheimer disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PRX-005
Drug type
Other
Therapy area
Neurology
Developer
BRISTOL MYERS SQUIBB (BMY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
H85U6L98FB

Conditions studied

Alzheimer Disease, Early Onset

More from BRISTOL MYERS SQUIBB

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind BMS-986446

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.